PT1086223E - Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações - Google Patents

Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações Download PDF

Info

Publication number
PT1086223E
PT1086223E PT99955273T PT99955273T PT1086223E PT 1086223 E PT1086223 E PT 1086223E PT 99955273 T PT99955273 T PT 99955273T PT 99955273 T PT99955273 T PT 99955273T PT 1086223 E PT1086223 E PT 1086223E
Authority
PT
Portugal
Prior art keywords
strap
family
prostate
human
expressed
Prior art date
Application number
PT99955273T
Other languages
English (en)
Portuguese (pt)
Inventor
Stephen Chappell Mitchell
Arthur B Raitano
Douglas C Saffran
Daniel E Afar
Rene S Hubert
Kahan Leong
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of PT1086223E publication Critical patent/PT1086223E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
PT99955273T 1998-06-01 1999-06-01 Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações PT1086223E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8752098P 1998-06-01 1998-06-01
US9118398P 1998-06-30 1998-06-30

Publications (1)

Publication Number Publication Date
PT1086223E true PT1086223E (pt) 2009-11-03

Family

ID=26777066

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99955273T PT1086223E (pt) 1998-06-01 1999-06-01 Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações

Country Status (13)

Country Link
US (10) US6329503B1 (cg-RX-API-DMAC7.html)
EP (2) EP1086223B1 (cg-RX-API-DMAC7.html)
JP (5) JP4855577B2 (cg-RX-API-DMAC7.html)
AT (1) ATE437947T1 (cg-RX-API-DMAC7.html)
AU (1) AU757698C (cg-RX-API-DMAC7.html)
CA (1) CA2328989C (cg-RX-API-DMAC7.html)
CY (1) CY1109509T1 (cg-RX-API-DMAC7.html)
DE (1) DE69941187D1 (cg-RX-API-DMAC7.html)
DK (1) DK1086223T3 (cg-RX-API-DMAC7.html)
ES (2) ES2329851T3 (cg-RX-API-DMAC7.html)
IL (2) IL139699A0 (cg-RX-API-DMAC7.html)
PT (1) PT1086223E (cg-RX-API-DMAC7.html)
WO (1) WO1999062941A2 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20020187472A1 (en) * 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) * 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2329851T3 (es) 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040048798A1 (en) * 1999-06-01 2004-03-11 Raitano Arthur B. Nucleic acid and corresponding protein entitle 98P4B6 useful in treatment and detection of cancer
US20040141975A1 (en) * 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU5416700A (en) * 1999-05-20 2000-12-12 Fahri Saatcioglu Differentially expressed genes in prostate cancer
DK1244705T3 (da) * 1999-12-06 2010-05-31 Agensys Inc Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf
EP1257585A2 (en) * 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
US7611892B2 (en) * 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
AU2001249411B2 (en) * 2000-03-24 2007-02-15 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
US7189565B2 (en) 2001-03-23 2007-03-13 Fahri Saatcioglu Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
CN101555283B (zh) 2001-01-17 2012-03-21 生物权威国际有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ES2537074T3 (es) * 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2002360670A1 (en) * 2001-12-19 2003-07-09 Wilk Patent Development Corporation Method and related composition employing nanostructures
ES2541351T3 (es) 2002-02-25 2015-07-17 Vaxiion Therapeutics, Llc Composiciones de minicélulas y procedimientos
AU2003256912A1 (en) * 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
JP5840351B2 (ja) * 2002-09-06 2016-01-06 アジェンシス,インコーポレイテッド 癌の処置および検出において有用な98p4b6と称される、核酸および対応タンパク質
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
KR101215179B1 (ko) 2004-04-22 2012-12-24 어젠시스 인코포레이티드 Steap-1 단백질과 결합하는 항체 및 그로부터 유래된분자
US8765164B2 (en) * 2005-10-21 2014-07-01 Kenneth W. Carpenter Poly(ester urea) polymers and methods of use
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原(psca)抗体
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
WO2008043145A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
DK2502938T3 (en) 2006-10-27 2015-04-20 Genentech Inc Antibodies and immunoconjugates and uses thereof
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック, インコーポレイテッド 抗CD79b抗体及びイムノコンジュゲートとその使用方法
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
SI2187965T1 (sl) 2007-08-17 2020-03-31 Purdue Research Foundation Office Of Technology Commercialization Konjugati vezalca ligand-veznika PSMA in metode za uporabo
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
AU2008299594B2 (en) 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
NZ583894A (en) 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
JP5951929B2 (ja) * 2007-10-03 2016-07-13 コーネル ユニヴァーシティー Psma抗体を用いる増殖性障害の治療
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
AU2009266430B2 (en) 2008-07-04 2014-08-14 Biosceptre International Limited Anti- P2X7 peptides and epitopes
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
ES2904911T3 (es) 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
KR20130098165A (ko) 2010-06-03 2013-09-04 제넨테크, 인크. 항체 및 면역접합체의 이뮤노-pet 영상화 및 그의 용도
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
WO2012057765A1 (en) 2010-10-28 2012-05-03 The Board Of Regents Of The University Of Texas System Recombinant anti-cd19 monoclonal antibodies
AU2015261742B2 (en) * 2010-11-12 2017-10-26 Inovio Pharmaceuticals, Inc. Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
KR101939150B1 (ko) * 2010-11-12 2019-01-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
DK2675474T3 (en) 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
EP2726095B1 (en) 2011-07-01 2018-06-06 Biosceptre (Aust) Pty Ltd Combination therapy
CN104067127A (zh) 2011-11-29 2014-09-24 霍夫曼-拉罗奇有限公司 用于前列腺癌分析的组合物和方法
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
KR101782623B1 (ko) 2013-07-10 2017-09-28 서울대학교산학협력단 복합 막횡단 단백질의 세포막외 펩타이드 항원 및 그의 용도
GEP20237497B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287731A1 (en) 2013-11-14 2016-10-06 Endocyte, Inc. Compounds for Positron Emission Tomography
EP3262071B8 (en) 2014-09-23 2022-05-18 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016205176A1 (en) 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
AU2016304764C1 (en) 2015-08-07 2023-06-01 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017106806A1 (en) 2015-12-18 2017-06-22 Federica Cavallo COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
US10772972B2 (en) * 2016-09-23 2020-09-15 Regeneron Pharmaceuticals, Inc. Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
JP7105235B2 (ja) 2016-12-01 2022-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫petイメージングのための放射性標識された抗pd-l1抗体
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
MX2019011769A (es) 2017-04-03 2019-11-07 Hoffmann La Roche Anticuerpos que se unen a steap-1.
EP3618869A4 (en) 2017-05-01 2021-01-20 Agilvax, Inc. COMPOSITIONS AND PROCEDURES RELATED TO XCT ANTIBODIES
JP7348844B2 (ja) 2017-06-07 2023-09-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 内部移行酵素のための組成物および方法
JP2021522193A (ja) 2018-04-17 2021-08-30 エンドサイト・インコーポレイテッドEndocyte, Inc. 癌を治療する方法
US12252544B2 (en) 2018-05-17 2025-03-18 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
MY208638A (en) 2018-07-02 2025-05-21 Amgen Inc Anti-steap1 antigen-binding protein
EP3823993A1 (en) * 2018-07-18 2021-05-26 Amgen Inc. Chimeric receptors to steap1 and methods of use thereof
US12473265B2 (en) 2019-05-20 2025-11-18 Endocyte, Inc. Methods for preparing PSMA conjugates

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
EP0914155B1 (en) * 1996-03-25 2006-02-22 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
US5859045A (en) 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
DE69734249T2 (de) * 1996-07-15 2006-07-13 Mayo Foundation For Medical Education And Research, Rochester Verfahren zur detektion der hk2 polypeptide
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
DE19641560A1 (de) * 1996-10-09 1998-04-16 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease
ES2290964T3 (es) 1996-10-15 2008-02-16 The Regents Of The University Of California Modelos animales de la evolucion del cancer de prostata humano.
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CN1195851C (zh) 1997-02-25 2005-04-06 科里克萨有限公司 用于前列腺癌免疫疗法的化合物及其用途
DK0972201T3 (da) 1997-02-25 2006-01-02 Corixa Corp Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2000035937A1 (en) 1998-12-17 2000-06-22 Human Genome Sciences, Inc. 47 human secreted proteins
JP2002516572A (ja) * 1997-05-23 2002-06-04 バイオジェン,インコーポレイテッド 組織の再生の調節
ATE338117T1 (de) 1997-08-01 2006-09-15 Serono Genetics Inst Sa 5' ests für proteine, die nicht gewebespezifisch sind
AU8555198A (en) 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in prostate
JPH11164691A (ja) 1997-10-03 1999-06-22 Rikagaku Kenkyusho 胚盤胞cDNA
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6255049B1 (en) * 1998-02-27 2001-07-03 The Trustees Of Columbia University In The City Of New York Detection of metastatic cancer cells using PCTA-1
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
ES2329851T3 (es) 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
KR20010083111A (ko) 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
WO2000077021A1 (en) 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 48 human secreted proteins
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
JP2003527089A (ja) 1999-08-17 2003-09-16 インサイト・ゲノミックス・インコーポレイテッド 膜関連タンパク質
GB2354821A (en) 1999-09-29 2001-04-04 Dine O Quick Threshold crossing counter
AU7994200A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001034802A2 (en) 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
DK1244705T3 (da) 1999-12-06 2010-05-31 Agensys Inc Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf
AU3447401A (en) 2000-01-14 2001-07-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020081590A1 (en) 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
AU2001249411B2 (en) 2000-03-24 2007-02-15 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
WO2001073032A2 (en) 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001094629A2 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
CA2412223A1 (en) 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
JP2004508019A (ja) 2000-07-28 2004-03-18 コンピュジェン インコーポレイテッド トランスクリプトームの中に場所を占めるrna転写物及びスプライス変異体を検出するためのオリゴヌクレオチドライブラリー
EP1445318A2 (en) 2000-08-24 2004-08-11 Genetech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2002030268A2 (en) 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
CA2429343A1 (en) 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
WO2002057303A2 (en) 2001-01-12 2002-07-25 Hybrigenics Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
EP1390390A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences Inc HUMAN SECRETED PROTEINS
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
US6918525B2 (en) * 2003-05-23 2005-07-19 Worktools, Inc. Spring energized desktop stapler
KR101215179B1 (ko) * 2004-04-22 2012-12-24 어젠시스 인코포레이티드 Steap-1 단백질과 결합하는 항체 및 그로부터 유래된분자
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US7056186B1 (en) * 2005-04-06 2006-06-06 Weyenberg Karey M Cleavage-enhancing foundation garment

Also Published As

Publication number Publication date
EP2080802A2 (en) 2009-07-22
US7968307B2 (en) 2011-06-28
DE69941187D1 (de) 2009-09-10
JP4871341B2 (ja) 2012-02-08
CY1109509T1 (el) 2014-08-13
EP1086223B1 (en) 2009-07-29
WO1999062941A3 (en) 2000-04-06
JP2002517184A (ja) 2002-06-18
EP1086223A2 (en) 2001-03-28
US8414898B2 (en) 2013-04-09
US20070104720A1 (en) 2007-05-10
US6329503B1 (en) 2001-12-11
US20030045682A1 (en) 2003-03-06
US20050064445A1 (en) 2005-03-24
ES2329851T3 (es) 2009-12-01
IL203524A (en) 2013-06-27
ES2629442T3 (es) 2017-08-09
AU4326299A (en) 1999-12-20
WO1999062941A8 (en) 2000-08-03
JP2014239695A (ja) 2014-12-25
US20100173297A1 (en) 2010-07-08
US7611904B2 (en) 2009-11-03
WO1999062941A2 (en) 1999-12-09
US20030055217A1 (en) 2003-03-20
US20110318371A1 (en) 2011-12-29
AU757698C (en) 2004-04-08
DK1086223T3 (da) 2009-11-30
ATE437947T1 (de) 2009-08-15
US20050202454A1 (en) 2005-09-15
JP2009106284A (ja) 2009-05-21
CA2328989C (en) 2012-02-07
WO1999062941A9 (en) 2000-09-14
US20100190962A1 (en) 2010-07-29
CA2328989A1 (en) 1999-12-09
JP2017079748A (ja) 2017-05-18
US7575749B2 (en) 2009-08-18
US7166714B2 (en) 2007-01-23
JP6371362B2 (ja) 2018-08-08
US6887975B2 (en) 2005-05-03
US7053186B2 (en) 2006-05-30
AU757698B2 (en) 2003-03-06
US7642054B2 (en) 2010-01-05
JP5683414B2 (ja) 2015-03-11
JP2012050434A (ja) 2012-03-15
IL139699A0 (en) 2002-02-10
EP2080802B1 (en) 2017-03-29
JP4855577B2 (ja) 2012-01-18
EP2080802A3 (en) 2009-08-05
US20060147951A1 (en) 2006-07-06
US7928201B2 (en) 2011-04-19

Similar Documents

Publication Publication Date Title
IL139699A0 (en) Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
IL199275A0 (en) Serpentine transmembrane sntigens expressed in human prostate cancers and uses thereof
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
FI964766A0 (fi) Keuhkopintaproteiinin SP-C synteettiset peptidianalogit
CA2092533A1 (en) Nucleotide sequences coding for a human protein with angiogenesis regulative properties
RU2002124123A (ru) Модифицированный фактор viii
PL336295A1 (en) Modified tnfalpha molecule, dna encoding such molecule and vaccine comprising such tnfalpha molecule and such dna
TR200100074T2 (tr) Nevrotrofik büyüme faktörü
FR2649982B1 (fr) Membrane biologique artificielle
DE69535719D1 (de) Fas-antigenbindender ligand
ES2060803T3 (es) Soporte biologico para cultivos celulares constituido por proteinas plasmaticas coaguladas por trombina, su utilizacion para el cultivo de los queratinocitos, su recuperacion y su transporte con fines de utilizacion terapeutica.
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
DE60226896D1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
WO2002022784A3 (en) Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
PT1200476E (pt) Proteínas e anticorpos antitumorais, e suas utilizações
WO2001098355A3 (en) Cgi-69 compositions and methods of use
WO2000004157A3 (en) Cloning and characterisation of novel mammalian peptidases
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
WO2001082948A3 (en) Uses of tgap7 for the modulation of leucocyte activation
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
UA40172A (uk) Спосіб пластики вихідного тракту правого шлуночка і легеневої артерії при радикальній корекції тетради фалло
NO20000694D0 (no) FremgangsmÕte for fremstilling av kontrastmidler som i utstrakt grad er fri for bivirkninger
MY143222A (en) Expression vector for animal cell